Presence of Glass Particles Prompts Recall of Octreotide Acetate Injection
To date, the Company has not received any reports of adverse reactions related to this recall.
Diagnosis & Disease Information
Recorlev Approved to Treat Endogenous Hypercortisolemia in Cushing Syndrome
The approval was based on data from two phase 3 studies that evaluated Recorlev in 166 adults with endogenous Cushing syndrome.
Skytrofa, a Once-Weekly Therapy for Pediatric Growth Hormone Deficiency, Now Available
The approval was based on data from the phase 3 heiGHt trial, which compared Skytrofa to somatropin in 161 treatment-naïve, prepubertal patients with growth hormone deficiency.
Skytrofa Approved as Once-Weekly Growth Hormone Deficiency Therapy
The approval was based on data from the phase 3 heiGHt trial that assessed Skytrofa in 161 treatment-naïve, prepubertal patients with growth hormone deficiency.
Levoketoconazole Under Review for Endogenous Cushing Syndrome
The NDA submission includes data from the phase 3 SONICS and LOGICS studies that evaluated levoketoconazole in adults with endogenous Cushing syndrome.
- Loading...
Loading...
Next post in News
Loading... 
Loading...